Transgenomic will provide reference laboratory services to Arup for the analysis of patient samples for mitochondrial DNA mutations, and mutations for other disorders
Transgenomic has developed expertise in analysing the whole mitochondrial genome, and proprietary tools have allowed the company to detect mutations in samples with less than 5% of mutated DNA.
In making the announcement, Transgenomic's president and chief executive officer, Craig Tuttle, stated, "We are very excited to enter into a relationship with Arup Laboratories.
"Arup is one of America's leading clinical diagnostic laboratories serving over 3000 hospitals today.
"This relationship will enable Transgenomic to provide a critical diagnostic service to hundreds of patients with mitochondrial disorders".
Noriko Kusukawa, vice president and director of new technology and licensing at Arup Laboratories, stated: "Mitochondrial diseases are a clinically heterogeneous group of disorders and are often difficult to diagnose.
"The incidence of this disease is much higher than previously thought and impacts about 1 in 8500 individuals in the USA.
"Transgenomic has expertise in mitochondrial genome analysis, and our relationship with Transgenomic will enable Arup to provide a much needed diagnostic service to physicians for the management of these serious diseases."
